Muroi Masashi

J-GLOBAL         Last updated: May 28, 2019 at 10:11
 
Avatar
Name
Muroi Masashi
Affiliation
Musashino University
Section
Faculty of Pharmacy Department of Pharmaceutical Sciences

Research Areas

 
 

Academic & Professional Experience

 
Apr 2019
 - 
Today
Professor, Musashino University
 
Apr 1998
 - 
Jun 1999
Chief Researcher
 
Jul 1999
 - 
Mar 2009
Head
 
Apr 2009
 - 
Mar 2019
Associate Professor
 

Education

 
 
 - 
Sep 1989
Toyama Medical and Pharmaceutical University
 

Published Papers

 
IRF1 supports DNA binding of STAT1 by promoting its phosphorylation.
Zenke K., Muroi M., Tanamoto K.
Immunol. Cell. Biol.   doi: 10.1111/imcb.12185    2018   [Refereed]
Zenke K., Muroi M., , Tanamoto K.
Cellular Signalling   43 32-39   2018   [Refereed]
Sugiyama K., Muroi M., Kinoshita M., Hamada O., Minai Y., Sugita-Konishi Y., Kamata Y., and Tanamoto K.
J. Toxicol. Sci.   41 273-279   2016   [Refereed]
Muroi M, Tanamoto K.
Toxicol. Lett.,   235 199-205   2015   [Refereed]
Kitajima T., Muroi M., Yamashita N., and Tanamoto K.
Biol. Pharm. Bull.   37 74-80   2014   [Refereed]
Shah N., de Oca M.M., Jover-Cobos M., Tanamoto K., Muroi M., Sugiyama K., Davies N.A., Mookerjee R.P., Dhar D.K., Jalan R.
Liver Transpl.   19 751-761   2013   [Refereed]
Ogura N., Muroi M., Sugiura Y.and Tanamoto K.
Pathogens and Disease   67 199-205   2013   [Refereed]
Muroi M., Shima K., Igarashi M., Nakagawa Y., and Tanamoto K.
Biol. Pharm. Bull.   35 1841-1845   2012   [Refereed]
Yoshida, T., Yoshioka, Y., Fujimura, M., Kayamuro, H., Yamashita, K., Higashisaka, K., Nakanishi, R., Morishita, Y., Nabeshi, H., Yamashita, T., Muroi, M., Tanamoto, K., Nagano, K., Abe, Y., Kamada, H., Kawai, Y., Mayumi, T., Itoh, N., Yoshikawa, T., Tsunoda, S., Tsutsumi, Y.
Biol. Pharm. Bull.   33 780-783   2010   [Refereed]
Ohnishi T., Muroi M., Tanamoto K.
Microbiol. Immunol.   54 74-80   2010   [Refereed]
Sugiyama K., Muroi M., Tanamoto K., Nishijima M., Sugita-Konishi Y.
Toxicol Lett.   192 150-4   2010   [Refereed]
Shioiri T., Muroi M., Hatao F., Nishida M., Ogawa T., Mimura Y., Seto Y., Kaminishi M., Tanamoto K.
Biochim. Biophys. Acta   1792 1011-1018   2009   [Refereed]
Muroi M, Tanamoto K.
J. Leuk. Biol.   83 702-707   2008   [Refereed]
Hatao F., Yamamoto M., Muroi M., Kaminishi M., Tanamoto K.
FEMS Immunol. Med. Microbiol.   53 260-264   2008   [Refereed]
Ohnishi T., Yoshida T., Igarashi A., Muroi M., Tanamoto K.
FEMS Immunol. Med. Microbiol.   52 293-295   2008   [Refereed]
Sugiyama K., Muroi M., Tanamoto K.
Eur. J. Pharmacol.   594 152-156   2008   [Refereed]
Ohnishi T., Muroi M., Tanamoto K.
FEMS Immunol. Med. Microbiol.   51 84-91   2007   [Refereed]
Yokota S., Ohnishi T., Muroi M., Tanamoto K., Fujii N., Amano K.
FEMS Immunol. Med. Microbiol.   51 140-148   2007   [Refereed]
Shimomura-Shimizu M, Sugiyama K, Muroi M, Tanamoto K.
Biochem. Biophys. Res. Commun   332 793-799   2006   [Refereed]

Misc

 
Muroi M, Tanamoto K.
J. Biol. Chem.   281 5484-91   2006   [Refereed]
Igarashi A., Ohtsu S., Muroi M., Tanamoto K.
Biol. Pharm. Bull.   29 2120-2122   2006   [Refereed]
Hatao F, Hiki N, Mimura Y, Ogawa T, Kojima J, Mafune K, Hawkins LD, Muroi M, Tanamoto K, Kaminishi M.
Shock   23 365-370   2005   [Refereed]
Hatao, F., Muroi, M., Hiki, N., Ogawa, T., Mimura, Y., Kaminishi, M., and Tanamoto, K.
J. Leuk. Biol.   76 904-908   2004   [Refereed]
Sakai,A., Kikuchi,Y., Muroi,M., Masui,T., Furihata,C., Uchida,E., Takatori,K., Tanamoto,K.
Biol. Pharm. Bull.   26 347-351   2003   [Refereed]
Fujihara, M., Muroi, M., Tanamoto, K., Suzuki, T., Azuma, H., Ikeda, H.
Pharmacol. Therapeut   100 171-194   2003
Ohnishi T., Muroi M., and Tanamoto K.
Clin. Diagn. Lab. Immunol.   10 405-410   2003   [Refereed]
Muroi, M., Ohnishi, T., and Tanamoto, K.
J. Biol. Chem.   277 42372-42379   2002   [Refereed]
Muroi, M., Ohnishi, T., and Tanamoto, K.
Infect. Immun.   70 3546-3550   2002   [Refereed]
N-linked glycosylations at Asn26 and Asn114 of human MD-2 are required for Toll-like receptor 4-mediated activation of NF-kB by lipopolysaccharide.
Ohnishi, T., Muroi, M., and Tanamoto, K.
J. Immunol.   167 3354-3359   2001   [Refereed]
Both basal and enhancer kB elements are required for full induction of the mouse inducible nitric oxide synthase gene.
Murphy W. J., Muroi M Zhang C.X., Suzuki T., and Russell S.W.
J. Endotoxin Res.   3 381-393   2000   [Refereed]
Effects of protease inhibitors on LPS-mediated activation of a mouse macrophage cell line (J774).
Muroi M., Muroi Y., Ito N., Rice N.R., and Suzuki T
J. Endotoxin Res.   2 337-347   1995   [Refereed]
Kimura M., Kimura I., Muroi M., Nojima H., and Diwan P. V.
Biol. Pharm. Bull.   18 691-695   1995   [Refereed]
Kimura M., Kimura I., Muroi M., Tanaka K., Nojima H., Uwano T., and Koizumi T.
Biol. Pharm. Bull.   17 1224-1231   1994   [Refereed]
Muroi M., and Suzuki T.
Cellular Signalling.   5 289-298   1993   [Refereed]
Mechanism of lipopolysaccharide-triggered junB activation in a mouse macrophage-like cell line. (J774).
Fujihara M., Muroi M., Muroi Y., Ito N., and Suzuki T.
J. Biol. Chem.   268 14898-14905   1993   [Refereed]
Influence of 3' half-site sequence of NF-kB motifs on the binding of lipopolysaccharide-activatable macrophage NF-kB proteins.
Muroi M., Muroi Y., Yamamoto K., and Suzuki T.
J. Biol. Chem.   268 19534-19539   1993   [Refereed]
Different modes of blockade by p-phenylene-polymethylene bis-ammonium compounds of the nicotinic acetylcholine receptor channel in skeletal muscle cells of mice.
Nojima H., Kimura I., Muroi M., and Kimura M.
J. Pharm. Pharmacol.   45 309-314   1993   [Refereed]
Indirect inhibitory effect of succinylcholine on acetylcholine-activated channel activities and its modulation by external Ca2+ in mouse skeletal muscles.
Nojima H., Muroi M., Kimura I., and Kimura M.
Br. J. Pharmacol.   105 23-26   1992   [Refereed]
Muroi M., Kimura I., and Kimura M.
Neuropharmacol..   29 567-572   1990   [Refereed]
Kimura M., Muroi M., Kimura I., Sakai S., and Kitagawa I
Jpn. J. Pharmacol.   48 290-293   1988   [Refereed]
Pharmacological evidence for an interaction between constituents (blend effect) of Japanese-Sino medicine 'Keishi-ka-zyutubu-to' in neuromuscular blockade in diabetic mice.
Kimura M., Kimura I., Muroi M., Yoshizaki M., and Hikino H.
Phytotherapy Res.   1 107-113   1987   [Refereed]
Kimura M., Kimura I., Nojima H., and Muroi M.
Jpn. J. Pharmacol.   40 251-256   1986   [Refereed]
Kimura M., Kimura I., Muroi M., Nakamura T., and Shibata S.
Jpn. J. Pharmacol.   41 263-265   1986   [Refereed]
Kimura M., Kimura I., Takahashi K., Muroi M., Yoshizaki M., Kanaoka M., and Kitagawa I.
Jpn. J. Pharmacol.   36 275-282   1984   [Refereed]

Conference Activities & Talks

 
Trichothecene mycotoxins inhibit MyD88-independent pathways of Toll-like receptors
Sugiyama, K., Kinoshita, M., Minai, Y., Muroi, M., Tanamoto, K. and Sugita-Konishi, Y
9th Joint Meeting of ICS-ISICR   2011   
IRAK-1-mediated negative regulation of Toll-like receptor signaling.
Masashi Muroi and Ken-ichi Tanamoto
International Union of Microbiological Societies 2011 Congress   2011   
Stimulation of Toll-like receptors leads to proteasome-dependent downregulation of TRAF6 through interaction with IRAK-1.
Masashi Muroi and Ken-ichi Tanamoto
Annual Meeting of The Society for Leukocyte Biology & The International Endotoxin and Innate Immunity Society   2010   
TRAF6 distinctively mediates MyD88- and IRAK-1-induced activation of NF-kB.
Masashi Muroi, Takahiro Ohnishi and Ken-ichi Tanamoto
10th Biennial Meeting of the International Endotoxin and Innate Immunity Society   2008   
New assay for biologically active of lipopolysaccharide using NF-kB activity in Toll-like receptor (TLR) 4/MD-2/CD14-transfected HEK293 cells.
Nishida M., Hatao F., Hiki N., Ogawa T., Mimura Y., Seto Y. Muroi M., and Tanamoto K.
10th Biennial Meeting of the International Endotoxin and Innate Immunity Society   2008   
Effect of deoxynivalenol on LPS signaling in macrophage.
Kei-ichi Sugiyama, Masashi Muroi, Ken-ichi Tanamoto, Motohiro Nishijima, Yoshiko Sugita-Konishi
The Society of Toxicology Annual Meeting   2008   
Effect of deoxynivalenol and nivalenol on LPS-induced nitric oxide production by mouse macrophages.
Kei-ichi Sugiyama1, Masashi Muroi, Ken-ichi Tanamoto, Motohiro Nishijima, Yoshiko Sugita-Konishi
10th Biennial Meeting of the International Endotoxin and Innate Immunity Society   2008   
Dimerization of intracellular domain of TLR4 is not required for the activation of MyD88-independent signaling pathway.
Takahiro Ohnishi, Masashi Muroi, Ken-ichi Tanamoto
10th Biennial Meeting of the International Endotoxin and Innate Immunity Society   2008   
Overexpression of IRAK-1 leads to proteasome-dependent downregulation of TRAF6.
Muroi M., and Tanamoto K.
Joint Meeting of the Society for Leukocyte Biology and the International Endotoxin and Innate Immunity Society   2006   
Novel lipopolysaccharide-recognition mechanism in cells expressing TLR4 and CD14 but lacking MD-2.
Ohnishi T., Igarashi A., Muroi M., and Tanamoto K.
Joint Meeting of the Society for Leukocyte Biology and the International Endotoxin and Innate Immunity Society   2006   
New approach for analyzing biological activity of lipopolysaccharide in blood.
Nishida M., Hatao F., Hiki N., Ogawa T., Mimura Y., Kaminishi M. Muroi M., and Tanamoto K.
Joint Meeting of the Society for Leukocyte Biology and the International Endotoxin and Innate Immunity Society   2006   
Isolation of peptides that inhibit lipopolisaccharide signaling using Toll-like receptor 4-baited yeast two-hybrid screening.
Sugiyama K., Muroi M., and Tanamoto K.
Joint Meeting of the Society for Leukocyte Biology and the International Endotoxin and Innate Immunity Society   2006   
Endotoxin-induced endothelial and macrophage cells apoptosis.
Shioiri T., Muroi M., Hatao F., Nishida M., Ogawa T., Mimura Y., Tanamoto K., and Kaminishi M.
Joint Meeting of the Society for Leukocyte Biology and the International Endotoxin and Innate Immunity SocietyJ   2006   
Effects of possible endocrine disrupting chemicals on Toll-like receptor 2 and 4 signaling.
Igarashi A., Muroi M., and Tanamoto K.
Joint Meeting of the Society for Leukocyte Biology and the International Endotoxin and Innate Immunity Society   2006   
Helicobacter pylori lipopolysaccharides, which have low endotoxic activity, upregulate Toll-like receptor 4 expression and enhance inflammatory reaction induced by other bacterial lipopolysaccharide.
Yokota S., Amano K., Ohnishi T., Okabayashi T., Yokosawa N., Muroi M., Tanamoto K. and Fujii N.
The 26th International Symposium of Sapporo Cancer Seminar   2006   
The function of N-linked glycosylations at Asn26 and Asn114 of human MD-2 on Toll-like receptor 4-mediated signal transduction.
Ohnishi, T., Muroi, M., and Tanamoto, K
7th Conference of the International Endotoxin Society, Washington D.C.   2002   
MD-2 is involved in species-specific actions of Salmonella lipid A.
Muroi, M., Ohnishi, T., and Tanamoto, K
7th Conference of the International Endotoxin Society, Washington D.C.   2002   
Different responses of macrophages via TLR4 to tetrasaccharide-type glycosphingolipids from Sphingomonas.
Kumazawa Y., Takimoto H., Kawahara K., Muroi M., Tanamoto K.
7th Conference of the International Endotoxin Society, Washington D.C.   2002   
Domain requirements of mouse CD14 molecule to enhance TLR2- and TLR4-mediated activation of NF-kB in response to lipopolysaccharide.
Masashi Muroi, Takahiro Ohnishi, Ken-ichi Tanamoto
6th Conference of the International Endotoxin Society   2000   
Protease inhibitors (PCK or TPCK) inhibit LPS-induced activation of transcription factors, cytokine and inducible nitric oxide synthase genes, and tumoricidal activity of a mouse macrophage cell line.
Muroi M., Muroi Y., Ito N., Rice N.R., and Suzuki T.
9th International Congress of Immunology   1995   
LPS-activated macrophage NF-kB proteins: Influence of 3' half site sequence of NF-kB motifs on the binding.
Muroi M., and Suzuki T.
AAI/CIS Joint Meeting   1993   
Involvement of protein kinase A in LPS-induced activation of NF-kB in a mouse macrophages.
Muroi M., and Suzuki T.
FASEB meeting   1992